SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity

SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity

Since the successful introduction of checkpoint inhibitors targeting the adaptive immune system, monoclonal antibodies inhibiting CD47-SIRPα interaction have shown promise in enhancing anti-tumor treatment efficacy. Apart from SIRPα, neutrophils express a broad repertoire of inhibitory receptors, in...

Full description

Bibliographic Details
Main Authors: Panagiota Bouti, Colin Blans, Bart J. A. M. Klein, Debarati Shome, Reza Nadafi, Michel Van Houdt, Karin Schornagel, Paul J. J. H. Verkuijlen, Virginie Roos, Rogier M. Reijmers, Robin Van Bruggen, Taco W. Kuijpers, Hanke L. Matlung
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:International Journal of Molecular Sciences
Subjects:
neutrophil ADCC
SIGLEC
sialic acid
checkpoint blockade
antibody therapy
Online Access:https://www.mdpi.com/1422-0067/24/24/17141

Internet

https://www.mdpi.com/1422-0067/24/24/17141

Similar Items